FOXO1: A Potential Target for Human Diseases

被引:86
|
作者
Lu, Huarui [2 ]
Huang, Haojie [1 ,2 ,3 ]
机构
[1] SUNY Stony Brook, Dept Pathol, Med Ctr, Stony Brook, NY 11794 USA
[2] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN 55455 USA
[3] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA
基金
美国国家卫生研究院;
关键词
FoxO transcription factors; posttranslational modification; apoptosis; the cell cycle; glucose metabolism; cancer; diabetes; muscle atrophy; FORKHEAD TRANSCRIPTION FACTOR; PROTEIN-KINASE-B; PROSTATE-CANCER CELLS; FACTOR FKHR; ANDROGEN RECEPTOR; LIFE-SPAN; NUCLEAR EXCLUSION; SKELETAL-MUSCLE; FAMILY-MEMBER; DNA-BINDING;
D O I
10.2174/138945011796150280
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The forkhead box O (FoxO) transcription factors are known to be involved in many physiological and pathological processes including apoptosis, cell cycle arrest, stress resistance, glucose metabolism, cellular differentiation and development, and tumor suppression. The environmental cues, such as growth factors, nutrients, oxidative stress and irradiation, can either positively or negatively modulate FoxO proteins' activities, thereby ensuring distinctive transcription programs in the cell. The potent activities of FoxOs are tightly controlled by multiple mechanisms, which include posttranslational modification such as phosphorylation, acetylation, methylation and ubiquitination, subcellular localization, and direct protein-protein interaction. Mounting evidence suggests that the human FOXO1 protein, a founding member of the FoxO family is likely involved in carcinogenesis, diabetes and other human diseases. Here we give an overview of most recent findings regarding the regulation and function of FoxO1, its potential role in human diseases and useful animal models for functional studies on FoxO1. Prospective ways in which the discoveries from the basic research of FoxO1 can be utilized for drug targeting and development of novel therapeutics for human diseases are also discussed.
引用
收藏
页码:1235 / 1244
页数:10
相关论文
共 50 条
  • [41] Diabetes: Selective FOXO1 modulation
    Crunkhorn S.
    Nature Reviews Drug Discovery, 2017, 16 (12) : 828 - 828
  • [42] Cytosolic FoxO1: alive and killing
    René H. Medema
    Marja Jäättelä
    Nature Cell Biology, 2010, 12 : 642 - 643
  • [43] Isotretinoin and FoxO1 A scientific hypothesis
    Melnik, Bodo C.
    DERMATO-ENDOCRINOLOGY, 2011, 3 (03) : 141 - 165
  • [44] FoxO1: A Molecule for All Seasons
    Kousteni, Stavroula
    JOURNAL OF BONE AND MINERAL RESEARCH, 2011, 26 (05) : 912 - 917
  • [45] Putting the brakes on FOXO1 in fat
    Kim, Jane J.
    Fan, Wuqiang
    Olefsky, Jerrold M.
    EMBO JOURNAL, 2012, 31 (10): : 2240 - 2241
  • [46] FOXO1 AS A POTENTIAL TUMOR SUPPRESSOR IS INACTIVATED BY ANDROGENS IN BLADDER CANCER CELLS
    Ide, Hiroki
    Inoue, Satoshi
    Li, Yi
    Zheng, Yichun
    Kashiwagi, Eiji
    Kawahara, Takashi
    Netto, George
    Miyamoto, Hiroshi
    JOURNAL OF UROLOGY, 2016, 195 (04): : E1088 - E1088
  • [47] Evaluation of FOXO1 Target Engagement Using a Single-Cell Microfluidic Platform
    Osman, Suhuur
    Bendtsen, Claus
    Peel, Samantha
    Yrlid, Linda
    Muthas, Daniel
    Simpson, John
    Willison, Keith R.
    Klug, David R.
    ANALYTICAL CHEMISTRY, 2021, 93 (44) : 14659 - 14666
  • [48] The Potential Role Of Foxo1 On Hyperglycemic Metabolic Stress And Asthmatic Lung Inflammation
    Chung, S.
    Lee, Y.
    Karpurapu, M.
    Qian, F.
    Deng, J.
    Ballinger, M. N.
    Christman, J. W.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [49] Candidate gene study of FOXO1, FOXO4, and FOXO6 reveals no association with human longevity in Germans
    Kleindorp, Rabea
    Flachsbart, Friederike
    Puca, Annibale A.
    Malovini, Alberto
    Schreiber, Stefan
    Nebel, Almut
    AGING CELL, 2011, 10 (04) : 622 - 628
  • [50] Mammalian target of rapamycin complex 1 and FoxO1 in the transcriptional control of lipolysis and de novo lipogenesis
    Kandror, Konstantin V.
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2017, 24 (05) : 326 - 331